Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787719 | 0.84 | HDAC1 (0.39) | RAB9AHDAC1HDAC8HDAC6HTT | |
| SCHEMBL787920 | 0.80 | ALDH1A1 (0.41) | KMT2APOLBHTT | |
| SCHEMBL661388 | 0.79 | HDAC1 (0.44) | KMT2APOLBHDAC1HDAC8HDAC6 | |
| SCHEMBL2335934 | 0.78 | HDAC6 (0.58) | KMT2AHDAC1HDAC8HDAC6 | |
| SCHEMBL29868403 | 0.70 | KMO (0.44) | KMT2APOLBHDAC1HDAC8HDAC6 | |
| SCHEMBL661562 | 0.70 | KMO (0.44) | KMT2APOLBHDAC1HDAC8HDAC6 | |
| SCHEMBL3070719 | 0.70 | CCR1 (0.55) | — | |
| SCHEMBL14615628 | 0.69 | NPC1 (0.40) | NPC1POLBRAB9AL3MBTL1 | |
| SCHEMBL2888546 | 0.69 | NOTUM (0.54) | HDAC1HDAC8HDAC6 | |
| SCHEMBL8705160 | 0.69 | ALDH3A1 (0.58) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | claimed |
| WO-2010103064-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | WO | claimed |
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | disclosed |
| WO-2010103064-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | PMP22, GRIN2C, NLN | KMT2A 1962/4885NPC1 254/4885POLB 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.